Mandate

Vinge has advised Randviken Fastigheter AB (publ) in connection with its change of company object and re-listing on Nordic SME

Vinge advises Randviken Fastigheter AB (publ) (”Randviken”) in connection with its change of company object and re-listing on Nordic SME (Nordic Growth Market). The Company Description was made public on 31 August 2021. The change of the company object was due to an indirect acquisition of 35 properties amounting to a total value of SEK 2,778 million.

Randviken is a real estate company with the aim to acquire, manage and refine properties in different segments and geographical locations. In addition to Randviken’s primary focus on stable and long-term cash flows from rented premises, the company’s ambition is to actively engage with intelligent technology to achieve more sustainable and energy efficient properties.

Randviken is listed on Nordic SME (Nordic Growth Market).

Vinges team included David Andersson, Julia Hirschberg and Olivia Belding (Capital Markets and Public M&A), Niclas Winnberg, Kristoffer Larson, Frida Ställborn and Ulf Pyk (Real Estate), as well as Fabian Ekeblad, Paulina Malmberg and Elin Samara (Banking and Finance).

 

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026